1. Pediatric high-grade glioma: aberrant epigenetics and kinase signaling define emerging therapeutic opportunities
   Yusha Sun et al, 2020, Journal of Neuro-Oncology CrossRef
2. Dual targeting of histone deacetylases and MYC as potential treatment strategy for H3-K27M pediatric gliomas
   Danielle Algranati et al, 2024, eLife CrossRef
3. Radiosensitization in Pediatric High-Grade Glioma: Targets, Resistance and Developments
   Dennis S. Metselaar et al, 2021, Frontiers in Oncology CrossRef
4. MGMT Expression Contributes to Temozolomide Resistance in H3K27M-Mutant Diffuse Midline Gliomas and MGMT Silencing to Temozolomide Sensitivity in IDH-Mutant Gliomas
   Hideaki ABE et al, 2018, Neurologia medico-chirurgica CrossRef
5. Evidence-Based Practice: Temozolomide Beyond Glioblastoma
   Jason Chua et al, 2019, Current Oncology Reports CrossRef
6. Small Molecule Inhibitors in Adult High-Grade Glioma: From the Past to the Future
   Wenda Huang et al, 2022, Frontiers in Oncology CrossRef
7. Glioblastoma: Current Status, Emerging Targets, and Recent Advances
   Amandeep Thakur et al, 2022, Journal of Medicinal Chemistry CrossRef
8. Diffuse midline glioma of the brainstem: genetic features, complications and treatment prospects
   A. M. Kryanev et al, 2024, Head and Neck Tumors (HNT) CrossRef